MAPK3 and neoplasm: The best in vivo antitumor response to sorafenib, i.e., a 70% TGI, was detected in NOD/SCID mice bearing HD-MyZ xenografts that showed a marked inhibition of both tumor and vascular ERK1/2 and Akt phosphorylation, suggesting that the concomitant inhibition of MAPK and PI3K/Akt signaling is required to achieve an optimal antilymphoma activity.